Patient characteristics.

<p>LBBB: left bundle branch block, LV EF: left-ventricular ejection fraction, LVEDD: left ventricular end-diastolic diameter, LVESD: left ventricular end-systolic diameter.</p

Comparison of optimal and worst LVPCs - Individual results in increment in mean %ΔLV +dP/dt_max (±95% confidence interval) in all patients in the optimal (white) and worst (grey) pacing configuration (p<0.0001 for all intraindividual differences).

<p>The red line indicates a 10% increase in LV +dP/dt_max, which has been proposed as a cut-off value to separate responders from non-responders (20). By this definition, individually tailoring the optimal pacing configurations in 4 patients (marked #) transformed non-responders into responders.</p

Averaged results over all patients - Box plots of %ΔLV +dP/dt_max, of all LVPCs, averaged over all 16 patients (5–95% percentile).

<p>RV stimulation consistently produced the least increase in LV +dP/dt_max. No differences were found between LVPCs with the same cathode.</p

Data_Sheet_1_Awake venovenous extracorporeal membrane oxygenation and survival.docx

ObjectivesDeep sedation on the ICU is linked to poor outcome. This study investigated the link between Richmond Agitation-Sedation Scale (RASS) and outcome in venovenous extracorporeal membrane oxygenation (V-V ECMO).MethodsWe performed a secondary analysis of a single-center V-V ECMO cohort. RASS was used as a surrogate measure of sedation depth, patients with a score ≥ −1 were considered awake. V-V ECMO durations below 24 h were excluded. Primary endpoint was 30-day survival. Secondary endpoints were hospital survival and weaning from both ventilator and ECMO therapy.ResultsA total of 343 patients were reanalyzed. The median age was 55 years and 52.2% (179/343) survived for 30 days after ECMO cannulation. Median duration of ECMO was 7.9 (4.7–15.0) days and the median duration of mechanical ventilation after ECMO cannulation was 11.8 (6.7–23.8) days.In the whole cohort, median RASS on day one and seven after ECMO were − 4 (−4 to −1) and − 3 (−4 to 0), respectively. ECMO survivors consistently had significantly higher RASS scores during the first 7 days of ECMO compared to non-surviving patients (p ConclusionIn this retrospective study, awake patients on V-V ECMO showed higher 30-day survival rates compared to sedated or unresponsive patients. These data should encourage further research on awake V-V ECMO.</p

Study flow chart – Distribution of the tested LVPCs.

<p>Study flow chart – Distribution of the tested LVPCs.</p

Transfusions of platelets, red blood cells and fresh frozen plasma; Percentage of patients requiring any transfusion (A), Average number of transfused blood products in all patients (B), Average number of transfused blood products in patients receiving at least one transfusion (C).

<p>Transfusions of platelets, red blood cells and fresh frozen plasma; Percentage of patients requiring any transfusion (A), Average number of transfused blood products in all patients (B), Average number of transfused blood products in patients receiving at least one transfusion (C).</p

Bleeding and transfusions.

<p>Bleeding and transfusions.</p

Dual Antiplatelet Therapy (DAPT) versus No Antiplatelet Therapy and Incidence of Major Bleeding in Patients on Venoarterial Extracorporeal Membrane Oxygenation

<div><p>Aims</p><p>Bleeding is a frequent complication in patients on venoarterial extracorporeal membrane oxygenation (VA-ECMO). An indication for dual antiplatelet therapy due to coronary stent implantation is present in a considerable number of these patients. The objective of this retrospective study was to evaluate if dual antiplatelet therapy (DAPT) significantly increases the high intrinsic bleeding risk in patients on VA-ECMO.</p><p>Methods and Results</p><p>A total of 93 patients were treated with VA-ECMO between October 2010 and October 2013. Average time on VA-ECMO was 58.9 ± 1.7 hours. Dual antiplatelet therapy was given to 51.6% of all patients. Any bleeding was recorded in 60.2% of all patients. There was no difference in bleeding incidence in patients on DAPT when compared to those without any antiplatelet therapy including any bleeding (66.7% vs. 57.1%, p = 0.35), BARC3 bleeding (43.8% vs. 33.3%, p = 0.31) or pulmonary bleeding (16.7% vs. 19.0%, p = 0.77). This holds true after adjustment for confounders. Rate of transfusion of red blood cells were similar in patients with or without DAPT (35.4% vs. 28.6%, p = 0.488).</p><p>Conclusions</p><p>Bleeding on VA-ECMO is frequent. This registry recorded no statistical difference in bleeding in patients on dual antiplatelet therapy when compared to no antiplatelet therapy. When indicated, DAPT should not be withheld from VA ECMO patients.</p></div

Bleeding incidence on venoarterial extracorporeal membrane oxygenation therapy, bleeding incidence during venoarterial extracorporeal membrane oxygenation therapy is given as percentage of patients with bleeding to total patients treated.

<p>Bleeding incidence on venoarterial extracorporeal membrane oxygenation therapy, bleeding incidence during venoarterial extracorporeal membrane oxygenation therapy is given as percentage of patients with bleeding to total patients treated.</p

Patients’ characteristics.

<p>Patients’ characteristics.</p